Cited by 131Per- and polyfluoroalkyl substances researchCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Severity of COVID-19 at elevated exposure to perfluorinated alkylates

Open access
Grandjean, Philippe, Timmermann, Clara Amalie Gade, Kruse, Marie, Nielsen, Flemming, Vinholt, Pernille Just, Boding, Lasse, Heilmann, Carsten, Mølbak, Kåre·2020·PLOS ONE

Published version of a preprint

Abstract

BACKGROUND: The course of coronavirus disease 2019 (COVID-19) seems to be aggravated by air pollution, and some industrial chemicals, such as the perfluorinated alkylate substances (PFASs), are immunotoxic and may contribute to an association with disease severity. METHODS: From Danish biobanks, we obtained plasma samples from 323 subjects aged 30-70 years with known SARS-CoV-2 infection. The PFAS concentrations measured at the background exposures included five PFASs known to be immunotoxic. Register data was obtained to classify disease status, other health information, and demographic variables. We used ordered logistic regression analyses to determine associations between PFAS concentrations and disease outcome. RESULTS: Plasma-PFAS concentrations were higher in males, in subjects with Western European background, and tended to increase with age, but were not associated with the presence of chronic disease. Of the study population, 108 (33%) had not been hospitalized, and of those hospitalized, 53 (16%) had been in intensive care or were deceased. Among the five PFASs considered, perfluorobutanoic acid (PFBA) showed an unadjusted odds ratio (OR) of 2.19 (95% confidence interval, CI, 1.39-3.46) for increasing severities of the disease. Among those hospitalized, the fully adjusted OR for getting into intensive care or expiring was 5.18 (1.29, 20.72) when based on plasma samples obtained at the time of diagnosis or up to one week before. CONCLUSIONS: Measures of individual exposures to immunotoxic PFASs included short-chain PFBA known to accumulate in the lungs. Elevated plasma-PFBA concentrations were associated with an increased risk of a more severe course of COVID-19. Given the low background exposure levels in this study, the role of exposure to PFASs in COVID-19 needs to be ascertained in populations with elevated exposures.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0244815

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PFAS exposure may leave the brain vulnerable to the deleterious impacts of infections, such as COVID-19, through attenuation of the adaptive immune system.

    “PFAS exposure may also leave the brain vulnerable to the deleterious impacts of infections, such as COVID-19 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), through attenuation of the adaptive immune system”

    From A Critical Review and Meta-Analysis of Impacts of Per- and Polyfluorinated Substances on the Brain and Behavior (2022) · cites this paper as Grandjean et al., 2020

    The Introduction (page not provided) describes PFAS as immunotoxic and links elevated exposure to lower vaccine-antibody responses. The Conclusions (page not provided) say PFAS exposure may contribute to COVID-19 severity. Neither passage addresses brain vulnerability, and the study does not establish attenuation of adaptive immunity as the mechanism for its COVID-19 finding. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Grandjean, P., Timmermann, C. A. G., Kruse, M., Nielsen, F., Vinholt, P. J., Boding, L., Heilmann, C., & Mølbak, K.
Affiliations
  • Harvard University (US)
  • University of Southern Denmark (DK)
  • Odense University Hospital (DK)
  • Statens Serum Institut (DK)
  • Rigshospitalet (DK)
Corresponding author
Grandjean, Philippe
Venue
PLOS ONE
Published
2020-12-31
Volume
15
Issue
12
Pages
e0244815
ISSN
1932-6203 (ISSN-L)
OpenAlex
W3114911023
Cited by
131
References
41
Citations by year
2026: 9 · 2025: 19 · 2024: 22 · 2023: 33 · 2022: 25 · 2021: 23
FWCI
7.51
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (submittedVersion, cc-by-nc-nd)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Novo Nordisk Fonden (NNF20SA0062871)
  • National Institute of Environmental Health Sciences (ES027706)
Topics
  • Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
COVID-19 pandemic, PFAS, perfluorobutanoic acid, disease severity, immunotoxicity, plasma PFAS concentrations, intensive care unit admission, mortality, industrial chemical exposure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review